Funding for this research was provided by:
National Key Research and Development Program of China Stem Cell and Translational Research (2017YFA0102600)
Strategic Priority Research Program of Chinese Academy of Sciences (XDA16030504)
National Natural Science Foundation of China (31801220)
Received: 19 April 2021
Accepted: 10 August 2021
First Online: 6 September 2021
: The H1 hES cell line used in the study was reviewed and approved by the Human Subject Research Ethics Committee at GIBH.
: Not applicable.
: Guangjin Pan is a member of the Editorial Board for Cell Regeneration. Guangjin Pan was not involved in the journal's review of, or decisions related to, this manuscript.